ABSTRACT
Aim and Method We aimed to study the clinical data and outcome of patients admitted in our centre with acute pulmonary embolism (PE) over a five year period from May 2013 to April 2018. The main outcome data included were- in-hospital bleeding, in hospital RV function improvement, PAH improvement, duration of hospital stay, 30 and 90 day mortality.
Results A total of 114 (69 m, 55 f) patients with the mean age of 55+/− 15 yrs were included. Patients who had involvement of central pulmonary trunk- called as “Central PE” group (n = 82) and others as “Peripheral PE” group (n = 32). There were more women in the peripheral PE group (53.1% vs 34.1%, p 0.05), while RBBB (22% vs 3.1%, p 0.02) and RV dysfunction (59.8% vs 25%, p 0.002) were noted more in the central PE group. Systemic thrombolysis was done in 53 patients (49 central, 4 peripheral), of which only 3 had hypotension and 28 patients were in the Intermediate-high risk group. The overall in-hospital, 30 day and 90 day mortality were 3.6, 13.2 and 22.8% respectively. Bleeding was significantly higher in thrombolysed group compared to the non- thrombolysed group (18.9% vs 0, p 0.0003). However, improvement in pulmonary hypertension was noted more in thrombolysis group compared to non-thrombolytic group. (49% vs 21.2%, p 0.01).
Conclusion This retrospective data from a tertiary centre in South India showed that short and mid-term mortality of patients with PE still remains high. The high non-guideline use of thrombolysis has reflected in the increased bleeding noted in our study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding involved
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Apollo Hospital Research Ethics committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.